In vitro and pharmacophore insights into CYP3A enzymes

Trends in Pharmacological Sciences

Volumn 24, Issue 4, 2003, Pages 161-166

  Ekins, Sean ^a   Stresser, David M ^b   Williams, J Andrew ^c  

^a 19034   (United States)

^b BD Biosciences   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 BENZYLOXY 4 TRIFLUOROMETHYLCOUMARIN; ALPHA NAPHTHOFLAVONE; ASTEMIZOLE; CISAPRIDE; CLOTRIMAZOLE; COUMARIN DERIVATIVE; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; ENZYME; ENZYME INHIBITOR; ERYTHROMYCIN; KETOCONAZOLE; MIBEFRADIL; MIDAZOLAM; NICARDIPINE; NIFEDIPINE; NIMODIPINE; TERFENADINE; TESTOSTERONE; TRIAZOLAM; TROLEANDOMYCIN; UNCLASSIFIED DRUG; VERAPAMIL;

DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; IC 50; LIGAND BINDING; MODEL; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

EID: 0037389628     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00049-X     Document Type: Review

References (45)

1. Wrighton S.A., et al. The human CYP3A subfamily: practical considerations. Drug Metab. Rev. 32:2000;339-361.
2. Kuehl P., et al. Sequence diversity in CYP3A promotors and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27:2001;383-391.
3. Domanski T.L., et al. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol. 59:2001;386-392.
4. Crespi C.L., et al. Design and application of fluorimetric assays for human cytochrome P450 inhibition. Methods Enzymol. 357:2002;276-284.
5. Stresser D.M., et al. Substrate-dependent modeulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorimetric substrates. Drug Metab. Dispos. 28:2000;1440-1448.
6. 50. J. Biomol. Screen. 7:2002;373-382.
7. Ekins S., et al. Present and future in vitro approaches for drug metabolism. J. Pharmacol. Toxicol. Methods. 44:2000;313-324.
8. Ekins S., et al. In vitro metabolism: subcellular fractions. Woolf T.F., et al. Handbook of Drug Metabolism. 1999;363-399 Marcel Dekker.
9. Hutzler J.M., Tracy T.S. Atypical kinetic profiles in drug metabolism reactions. Drug Metab. Dispos. 30:2002;355-362.
10. Korzekwa K.R., et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate-models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry. 37:1998;4137-4147.
11. Ekins S., et al. Autoactivation and activation of cytochrome P450s. Int. J. Clin. Pharmacol. Ther. 36:1998;642-651.
12. Maenpaa J., et al. Human cytochrome P4503A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by a-napthoflavone, terfenadine and testosterone. Pharmacogenetics. 8:1998;137-155.
13. 2+. Drug Metab. Dispos. 28:2000;1198-1201.
14. Wang R.W., et al. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab. Dispos. 28:2000;360-366.
15. Kenworthy K.E., et al. CYP3A4 drug interactions: correlation of ten in vitro probe substrates. Br. J. Clin. Pharmacol. 48:1999;716-727.
16. Domanski T.L., et al. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry. 40:2001;10150-10160.
17. Hosea N.A., et al. Elucidation of distinct ligand binding sites for the cytochrome P450 3A4. Biochemistry. 39:2000;5929-5939.
18. Shou M., et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry. 33:1994;6450-6455.
19. Shou M., et al. A kinetic model for the metabolic interaction of the two substrates at the active site of cytochrome P450 3A4. J. Biol. Chem. 276:2001;2256-2262.
20. Schrag M.L., Wienkers L.C. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch. Biochem. Biophys. 391:2001;49-55.
21. Domanski T.L., et al. Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and α-napthoflavone stimulation. Arch. Biochem. Biophys. 350:1998;223-232.
22. Ekins S., et al. Three dimensional quantitative structure activity relationship (3D-QSAR) analysis of CYP3A4 substrates. J. Pharmacol. Exp. Ther. 291:1999;424-433.
23. Koley A.P., et al. Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. Biochem. Pharmacol. 53:1997;455-460.
24. Atkins W.M., et al. Allosteric behavior in cytochrome P450-dependent in vitro drug-drug interactions: A prospective based on conformational dyamics. Chem. Res. Toxicol. 14:2001;338-347.
25. Ekins S., et al. Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J. Comput. Aided Mol. Des. 16:2002;381-401.
26. Ekins S., Rose J.P. In silico ADME/TOX: the state of the art at the 220th ACS meeting. J. Mol. Graph. 20:2002;305-309.
27. Ekins S., et al. Progress in predicting human ADME parameters in silico. J. Pharmacol. Toxicol. Methods. 44:2000;251-272.
28. Lipinski C.A. Avoiding investment in doomed drugs is poor solubility an industry wide problem? Curr. Drug Discov. 2001;. April, 17-19.
29. Johnson D.E., et al. Chem-tox informatics: data mining using a medicinal chemistry block approach. Curr. Opin. Drug. Discov. Dev. 4:2001;1.
30. Ekins S., et al. Pharmacophore and three dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab. Dispos. 29:2001;936-944.
31. Ekins S., et al. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of inhibitors for CYP3A4. J. Pharmacol. Exp. Ther. 290:1999;429-438.
32. Riley R.J., et al. development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharm. Res. 18:2001;652-655.
33. de Groot M.J., Ekins S. Pharmacophore modeling of cytochromes P450. Adv. Drug Deliv. Rev. 54:2002;367-383.
34. Stresser D.M., et al. Role of CYP3A5 and CYP3A7 in drug-drug interactions. Drug Metab. Rev. 33:(Suppl. 1):2001;134.
35. Williams J.A., et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. 30:2002;883-891.
36. 1 oxidation. Chem. Res. Toxicol. 14:2001;483-491.
37. He Y.A., et al. Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis. Biochemistry. 36:1997;8831-8839.
38. Harlow G.R., Halpert J.R. Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P4503A4. J. Biol. Chem. 272:1997;5396-5402.
39. Domanski T.L., et al. Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. J. Pharmacol. Exp. Ther. 293:2000;585-591.
40. Szklarz G.D., Halpert J.R. Molecular modeling of cytochrome P4503A4. J. Comput. Aided Mol. Des. 11:1997;265-272.
41. Treluyer J.-M., et al. Evidence of impaired cisapride metabolism in neonates. Br. J. Clin. Pharmacol. 52:2001;419-425.
42. Kitada M., et al. P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate. J. Biol. Chem. 262:1987;13534-13537.
43. Gorski J.C., et al. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47:1994;1643-1653.
44. Chen H., et al. Catalysis of the 4-hydroxylation of retinoic acids by CYP3A7 in human fetal hepatic tissues. Drug Metab. Dispos. 28:2000;1051-1057.
45. Jhoti H., et al. Crystal structure of a human cytochrome P450 enzyme. Drug Metab. Rev. 34:(Suppl. 1):2002;10.